Home > Boards > US Listed > Medical - Drugs > Merck & Co. Inc. (MRK)

Keytruda-monotherapy PDUFA in adjuvant melanoma is 2/16/19: #msg-141775785.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 724
Posts 109,582
Boards Moderated 15
Alias Born 09/05/02
160x600 placeholder
NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®) GlobeNewswire Inc. - 11/12/2019 9:00:00 AM
Gossamer in Agreement with Merck for Solid Tumor Studies Dow Jones News - 11/12/2019 7:56:00 AM
BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th GlobeNewswire Inc. - 11/12/2019 6:30:00 AM
Merck Gets Conditional European Commission Approval for Ebola Vaccine Dow Jones News - 11/11/2019 3:58:00 PM
Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union Business Wire - 11/11/2019 3:00:00 PM
NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 11/6/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 4:45:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/1/2019 5:08:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/1/2019 5:08:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/1/2019 5:07:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/1/2019 5:05:06 PM
Merck Raises 2019 Revenue, Adjusted Earnings Guidance Dow Jones News - 10/29/2019 8:02:00 AM
Merck Posts Higher 3Q Sales Dow Jones News - 10/29/2019 7:40:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/29/2019 6:51:07 AM
Merck Announces Third-Quarter 2019 Financial Results Business Wire - 10/29/2019 6:45:00 AM
BriaCell Announces Voting Results of the Special Meeting of Shareholders GlobeNewswire Inc. - 10/24/2019 6:30:05 AM
NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Va... GlobeNewswire Inc. - 10/21/2019 4:30:05 PM
Merck Gets Positive EU CHMP Opinion for Two New Regimens of Keytruda Dow Jones News - 10/18/2019 7:50:00 AM
Merck Gets CHMP Positive Opinion for V920 Ebola Zaire Virus Vaccine Dow Jones News - 10/18/2019 7:37:00 AM
Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metast... Business Wire - 10/18/2019 7:00:00 AM
Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disea... Business Wire - 10/18/2019 6:45:00 AM
BriaCell Announces Closing of Non-Brokered Private Placement of $568,444 GlobeNewswire Inc. - 10/15/2019 5:33:25 PM
BriaCell Therapeutics Corp. to File Amendment to Management Information Circular GlobeNewswire Inc. - 10/8/2019 7:00:00 PM
Merck Cuts Emissions by 7% Dow Jones News - 10/8/2019 9:55:00 AM
Merck Issues 2018/2019 Corporate Responsibility Report Business Wire - 10/8/2019 8:00:00 AM
DewDiligence Member Level  Monday, 06/25/18 11:53:53 AM
Re: None
Post # of 495 
Keytruda-monotherapy PDUFA in adjuvant melanoma is 2/16/19: #msg-141775785.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist